Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.

Finasteride solution helps treat hair loss.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This study developed and validated a precise and rapid HPLC method to simultaneously determine Minoxidil and Finasteride in pharmaceuticals, demonstrating successful application for routine quality control without interference from excipients.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This randomized, double-blind, placebo-controlled phase III trial found that a 24-week treatment with topical finasteride significantly increased hair growth and was well-tolerated in Chinese men with androgenetic alopecia compared to placebo.

Combination therapy with QR 678 Neo and 5% Minoxidil is most effective for male hair loss.

This meta-analysis found that the combination of topical minoxidil-finasteride was more effective than minoxidil alone in improving hair density, hair diameter, and global photographic assessment for male androgenetic alopecia, though larger standardized trials are needed to confirm long-term outcomes.

Combining platelet-rich plasma with 5% minoxidil solution improves hair regrowth in androgenetic alopecia patients.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This study found that combining microneedling with 5% Minoxidil and Finasteride significantly improved hair density and hair shaft diameter in males with androgenetic alopecia, outperforming Minoxidil alone or in combination with Finasteride, although changes in hormonal levels and trace elements were not significant.

In this study, the therapeutic response of topical minoxidil solution was not significantly enhanced by adding topical finasteride, questioning its additional value in treating male pattern androgenetic alopecia.

This study found that a topical combination of 0.25% finasteride and 3% minoxidil may increase hair diameter more effectively than 3% minoxidil alone in postmenopausal women with female pattern hair loss.

This study found that combining topical finasteride with IPL + RF hair removal significantly reduced unwanted facial hair in women after six months compared to placebo.

Combination of minoxidil and finasteride is more effective in increasing hair diameter than minoxidil alone for female-pattern hair loss.

P-3074 effectively blocks scalp DHT better than oral finasteride.

In this study, researchers developed and validated a rapid and robust chromatographic method to assess the concentration of Minoxidil and Finasteride in a new topical formulation for alopecia, demonstrating its ability to distinguish between different types of formulations using in vitro diffusion data.

This study found that a topical compounded formulation may improve hair density and general appearance in male patients with androgenetic alopecia after 6 months of use.

This study evaluated the stability of multiple active ingredients in TrichoSol™ for use in alopecia treatments, finding varying stability durations at room temperature—up to 180 days for some ingredients—supporting its use as a compounding vehicle in personalized therapies.

This research found that liquid-state liposomes and niosomes may enhance finasteride delivery to pilosebaceous units in hamsters more effectively than gel-state vesicles or hydroalcoholic solution.

This study found that Finasteride may spontaneously diffuse into an SDS-based model cell membrane at a significant rate, with distinct behavior in polar and non-polar solutions.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

This review evaluates various topical treatments for androgenetic alopecia but does not provide new clinical findings, emphasizing the need for selecting therapies with limited systemic side effects.

This study found that using gallate-containing formulations like EGCG or tannic acid increased the solubility and controlled release of finasteride in microspheres, enhancing its dermal penetration in pig skin by 10 to 50 times compared to a control.

This study found that adding topical finasteride 0.5% to diode laser therapy significantly reduced unwanted facial hair in women with idiopathic hirsutism compared to laser treatment with a placebo.

This study demonstrated that liquid-state vesicles may reduce the absorption of finasteride through the skin while increasing its concentration and retention in the dermis layer in hamster models.

In this study, ethosomes were found to significantly enhance the transdermal penetration and skin accumulation of finasteride compared to liposomes and other control solutions.

This study aims to develop three topical formulations of finasteride to reduce its side effects for treating androgenic alopecia.